[ad_1]
San Francisco, June 12, 2021 (Global News Agency)-Hagens Berman urges Emergent BioSolutions Inc. (New York Stock Exchange:EBS) Investors who lost $100,000 or more Submit your loss immediately.
class time: April 24th, 2020-April 16th, 2021
Deadline for lead plaintiff: June 18, 2021
access: www.hbsslaw.com/investor-fraud/ebs
Contact a lawyer immediately: EBS@hbsslaw.com
844-916-0895
Emergency Biological Solution (NYSE stock code:EBS) Securities Fraud Class Action:
Throughout the course, the defendant touted Emergent’s deal to produce vaccine candidates for Johnson & Johnson and AstraZeneca, as well as its “proven production capacity” at its Baltimore, Maryland plant.
In fact, the company concealed a large number of manufacturing problems at its Baltimore plant.
On March 31, 2021, media reports revealed that the company had confused the ingredients of Johnson & Johnson and AstraZeneca vaccines, contaminating as many as 15 million doses of Johnson & Johnson vaccine.
This news caused Emergent’s stock price to fall. Shortly before this disclosure, the CEO of Emergent sold $10 million in shares.
April 6, 2021 New York Times The report stated that the audit found that Emergent did not follow basic industry standards at its Baltimore plant. The audit conducted by AstraZenica highlighted the risk of virus cross-contamination.This right now It is further reported that starting from October 2020, Emergent has discarded five batches of AstraZeneca vaccines and a batch of Johnson & Johnson vaccines due to pollution or corruption.
Finally, on April 19, 2021, the company revealed that, at the request of the FDA, Emergent has stopped production at its Bayview plant, waiting for the FDA’s inspection to be completed.
“We focused on the investor’s losses and proved that Emergent lied about its vaccine production capabilities,” said Reed Kathrein, a partner at Hagens Berman, who led the investigation.
If you are an emergency investor and have suffered major losses, or have knowledge that may help the company’s investigations, Click here to discuss your legal rights with Hagens Berman.
Reporter: Those who have non-public information about Emergent should consider their options to help investigate or take advantage of the SEC whistleblower program. According to the new plan, whistleblowers who provide original information may be rewarded up to 30% of the successful recovery by the SEC. For more information, please call Reed Kathrein 844-916-0895 Or email EBS@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national law firm with eight offices and more than 80 lawyers in eight cities across the country. The company represents investors, whistleblowers, workers and consumers in complex litigation.For more information about the company and its success, please visit hbsslaw.com. For the latest news, please visit our Editorial department Or follow us on Twitter @classactionlaw.
contact:
Reed Catherine, 844-916-0895
[ad_2]
Source link
